CSPC Pharmaceutical Group Limited (HKG:1093)
Hong Kong · Delayed Price · Currency is HKD 9.69
+0.08 (0.78%)
Sep 4, 2026, 4:08 PM HKT
CSPC Pharmaceutical Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 31,327 | 26,006 | 29,009 | 31,450 | 30,937 | 27,867 | |
Revenue Growth | 20.50% | -10.35% | -7.76% | 1.66% | 11.02% | 11.73% |
Cost of Revenue | 8,818 | 8,947 | 8,711 | 9,273 | 8,680 | 6,732 |
Gross Profit | 22,509 | 17,059 | 20,299 | 22,177 | 22,256 | 21,135 |
Selling, General & Admin | 7,616 | 7,289 | 9,742 | 10,330 | 11,510 | 11,453 |
Research & Development | 6,156 | 5,809 | 5,191 | 4,830 | 3,987 | 3,433 |
Operating Expenses | 13,772 | 13,097 | 14,933 | 15,161 | 15,497 | 14,886 |
Operating Income | 8,737 | 3,961 | 5,366 | 7,016 | 6,760 | 6,249 |
Interest Expense | -30.26 | -38.6 | -43.67 | -25.9 | -24.89 | -7.66 |
Interest & Investment Income | 192.8 | 195.87 | 232.5 | 259.88 | 242.53 | 183.24 |
Earnings From Equity Investments | -43.6 | -52.45 | -89.47 | -54.2 | -15.4 | 22.44 |
Currency Exchange Gain (Loss) | -188.67 | -33.91 | 19.79 | 102.53 | 118.13 | -35.96 |
Other Non Operating Income (Expenses) | 368.44 | 457.13 | 221.31 | 246.21 | 315.32 | 172.63 |
EBT Excluding Unusual Items | 9,036 | 4,489 | 5,707 | 7,545 | 7,395 | 6,584 |
Gain (Loss) on Sale of Investments | 206.55 | 335.5 | -104.47 | -90.62 | 266.41 | 323.94 |
Gain (Loss) on Sale of Assets | -22.6 | -16.47 | -23.4 | -22.23 | -7.36 | -10.79 |
Asset Writedown | - | - | - | -42.32 | -72.11 | -50 |
Pretax Income | 9,220 | 4,808 | 5,579 | 7,389 | 7,582 | 6,847 |
Income Tax Expense | 1,457 | 931.73 | 1,240 | 1,317 | 1,350 | 1,159 |
Earnings From Continuing Operations | 7,763 | 3,876 | 4,339 | 6,073 | 6,232 | 5,688 |
Minority Interest in Earnings | -334.05 | 5.72 | -10.79 | -199.37 | -140.66 | -82.94 |
Net Income | 7,428 | 3,882 | 4,328 | 5,873 | 6,091 | 5,605 |
Net Income to Common | 7,428 | 3,882 | 4,328 | 5,873 | 6,091 | 5,605 |
Net Income Growth | 92.67% | -10.30% | -26.31% | -3.58% | 8.67% | 8.63% |
Shares Outstanding (Basic) | 11,408 | 11,424 | 11,738 | 11,872 | 11,917 | 11,953 |
Shares Outstanding (Diluted) | 11,417 | 11,424 | 11,738 | 11,873 | 11,919 | 11,954 |
Shares Change | -1.02% | -2.68% | -1.14% | -0.38% | -0.29% | -0.01% |
EPS (Basic) | 0.65 | 0.34 | 0.37 | 0.49 | 0.51 | 0.47 |
EPS (Diluted) | 0.65 | 0.34 | 0.37 | 0.49 | 0.51 | 0.47 |
EPS Growth | 94.63% | -7.84% | -25.47% | -3.21% | 9.00% | 8.64% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 3,872 | 2,519 | 2,555 | 5,407 | 3,226 |
Free Cash Flow Per Share | - | 0.34 | 0.21 | 0.21 | 0.45 | 0.27 |
Dividend Per Share | 0.289 | 0.261 | 0.238 | 0.258 | 0.191 | 0.152 |
Dividend Growth | 28.18% | 9.50% | -7.75% | 35.08% | 25.66% | 41.58% |
Gross Margin | 71.85% | 65.59% | 69.97% | 70.51% | 71.94% | 75.84% |
Operating Margin | 27.89% | 15.23% | 18.50% | 22.31% | 21.85% | 22.43% |
Profit Margin | 23.71% | 14.93% | 14.92% | 18.68% | 19.69% | 20.11% |
Free Cash Flow Margin | - | 14.89% | 8.69% | 8.12% | 17.48% | 11.58% |
EBITDA | 9,861 | 5,110 | 6,451 | 7,934 | 7,611 | 6,974 |
EBITDA Margin | 31.48% | 19.65% | 22.24% | 25.23% | 24.60% | 25.02% |
D&A For EBITDA | 1,124 | 1,149 | 1,085 | 918.47 | 851.62 | 724.39 |
EBIT | 8,737 | 3,961 | 5,366 | 7,016 | 6,760 | 6,249 |
EBIT Margin | 27.89% | 15.23% | 18.50% | 22.31% | 21.85% | 22.43% |
Effective Tax Rate | 15.80% | 19.38% | 22.23% | 17.82% | 17.81% | 16.93% |